In a randomised phase II trial in advanced melanoma resistant to anti-PD-(L)1 therapy, objective response rate was 9.3% with ceralasertib plus durvalumab (below the prespecified minimum threshold) and 5.8% with ceralasertib alone; median PFS was 2.0 vs 1.9 months.
RCT
Schlaak et al. MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition